Label: information for the user
Esomeprazole Demo 40mg Powder for injectable solution and for infusion EFG
Esomeprazole
Read this label carefully before starting to use this medication, as it contains important information for you.
Contents of the package and additional information
Esomeprazol Demo contains a medicine called esomeprazol that belongs to a group of medicines called proton pump inhibitors. These work by reducing the amount of acid produced by the stomach.
Esomeprazol Demo is used for the short-term treatment of certain disorders, when oral treatment is not possible. It is used for the treatment of the following disorders:
Adults
Children and adolescents aged 1 - 18 years
You should not take Esomeprazol Demo:
If you find yourself in any of these situations, you should not use Esomeprazol Demo. If you are unsure, consult your doctor or nurse before they administer this medication to you.
Warnings and precautions
Consult your doctor or nurse before starting to use Esomeprazol Demo if:
If you have a skin rash, especially in sun-exposed areas, inform your doctor as soon as possible, as you may need to stop treatment with Esomeprazol Demo. Remember to also mention other negative effects such as joint pain
Esomeprazol may mask symptoms of other diseases.Therefore, if you observe any of the following events before taking Esomeprazol or after its administration, contact your doctor immediately:
Taking a proton pump inhibitor like Esomeprazol Demo, especially for a period of more than one year, may slightly increase the risk of breaking a hip, wrist, or spine. Inform your doctor if you have osteoporosis or if you are taking corticosteroids (which may increase the risk of osteoporosis).
Use of Esomeprazol Demo with other medications
Inform your doctor or nurse if you are using, have used recently, or may need to use any other medication, even those acquired without a prescription. This is because Esomeprazol may affect how some medications work and some medications may influence the effect of Esomeprazol.
You should not use Esomeprazol if you are taking a medication that contains nelfinavir (used for HIV treatment).
Inform your doctor or nurse if you are taking any of the following medications:
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor, pharmacist, or nurse before using this medication. Your doctor will decide if you can take Esomeprazol during this period.
The passage of Esomeprazol into breast milk is unknown. Therefore, do not take Esomeprazol during breastfeeding.
Driving and operating machinery
Esomeprazol is unlikely to affect your ability to drive or use tools or machines.
However, rare side effects such as dizziness or vision disturbances (see section 4) may occur. If they do, patients should not drive or use machines
Esomeprazol Demo contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per vial; it is essentially "sodium-free".
Esomeprazol Demo can be administered to children and adolescents aged 1–18 years and to adults, including elderly patients.
Administration of Esomeprazol Demo
Use in adults
Use in children and adolescents
If you are given more Esomeprazol Demo than you should
If you think you have been given too much Esomeprazol Demo, speak immediately with your doctor.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
If you notice any of the following serious side effects, stop taking EsomeprazolDemoand contact a doctor immediately:
These side effects are rare and may affect 1 in 1,000 people.
Other side effects include:
Frequent (may affect up to 1 in 10 people)
Occasional (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Side effects of unknown frequency (cannot be estimated from available data)
In rare cases, EsomeprazolDemomay affect white blood cells, causing immunodeficiency. If you have an infection with symptoms such as fever with asevere worseningof the general condition or fever with symptoms of a local infection such as neck pain, throat pain, mouth pain, or difficulty urinating, you should consult your doctor as soon as possible to rule out a decrease in the number of white blood cells (agranulocytosis) through a blood test. It is essential to report your medication in this case.
Reporting side effects
If you experience any type of side effect, consult your doctor,pharmacistor nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: www.notificaram.es.
By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Shelf life after reconstitution
Chemical and physical stability has been demonstrated for use within 12 hours at (30 ± 2)° C. From a microbiological standpoint, the product should be used immediately.
Store below 30 °C.
Composition of Esomeprazol Demo
- The active ingredient is esomeprazole sodium. Each vial of powder for injectable solution and for infusion contains 42.6 mg of esomeprazole sodium, equivalent to 40 mg of esomeprazole.
- The other components are disodium edetate and sodium hydroxide. See section 2
Appearance of the product and contents of the package
Esomeprazol Demo is a porous cake or white to off-white powder. Before its administration, it is reconstituted into a solution.
Presentations: 1, 5, 10, 20 vials.Some package sizes may only be marketed.
Marketing authorization holder and responsible manufacturer
DEMO S.A., PHARMACEUTICAL INDUSTRY, 21st km National Road Athens-Lamia, 14568 Krioneri, Attiki, Greece
This medicine is authorized in the member states of the European Economic Area with the following names:
Germany: | Esomeprazole DEMO 40 mg Powder for the preparation of an injection and infusion solution |
Greece: | DEMOLOX 40 mg Κ?νις για εν?σιμο δι?λυμα και δι?λυμα προς ?γχυση |
Spain: | Esomeprazol Demo 40mg Powder for injectable solution and for infusion EFG |
Cyprus: | DEMOLOX 40 mg Κ?νις για εν?σιμο δι?λυμα και δι?λυμα προς ?γχυση |
Netherlands: | Esomeprazol DEMO 40 mg poeder voor oplossing voor injectie/infusie |
Last review date of this leaflet:07/2020.
For detailed information about this medicine, please visit the website of the Spanish Agency of Medicines and Medical Deviceshttp://www.aemps.es
This information is intended solely for healthcare professionals:
Esomeprazol DEMO 40 mg contains 40 mg of esomeprazole, as sodium salt. Each vial also contains disodium edetate and sodium hydroxide (<1>
The vials are for single use. If the reconstituted solution is not used completely for a single dose, it must be discarded.
For more information on dosage recommendations and storage conditions, see the sections below
Preparation and administration of the reconstituted solution:
The reconstituted solution for injection or infusion must be transparent and colorless to slightly yellow. The reconstituted solution must be visually inspected for particles and discoloration before administration. Only the transparent solution should be used.
Chemical and physical stability has been demonstrated for 12 hours at 30 ± 2° C. From a microbiological point of view, the product must be used immediately.
Esomeprazole Demo Injection
To prepare a solution for injection:
Injection of 40 mg
To prepare a solution for injection (8 mg/ml), add 5 ml of sodium chloride 0.9% for intravenous use to the vial of esomeprazole 40 mg.
The reconstituted solution for injection must be administered intravenously over a period of at least 3 minutes.
For more information on the administration of doses, please see the technical data sheet, section 4.2.
Esomeprazole Demo Infusion
To prepare a solution for infusion:
Infusion 40 mg
To prepare a solution for infusion, dissolve the contents of a vial of esomeprazole 40 mg in up to 100 ml of sodium chloride 0.9% for intravenous use.
Infusion 80 mg
To prepare a solution for infusion, dissolve the contents of two vials of esomeprazole 40 mg in up to 100 ml of sodium chloride 0.9% for intravenous use.
For more information on the administration of the dose, please consult the technical data sheet, section 4.2.
Elimination
Any remaining medication or waste material should be disposed of in accordance with local procedures.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.